Chronic Recurrent Chilblains (Pernio, Investigational Adjunct)
Investigational adjunct for chronic recurrent chilblains; cold avoidance, smoking cessation, calcium channel blockers (nifedipine), and topical corticosteroids remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for chilblains (perniosis). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic recurrent chilblains is investigational.
- What evidence exists?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based therapy for chilblains: cold and moisture avoidance (strict), warm gloves and footwear, smoking cessation, and topical or oral nifedipine for refractory cases. Workup for underlying connective tissue disease (lupus, antiphospholipid syndrome, cryoglobulinemia, COVID-19 chilblain-like lesions) in atypical presentations.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of cold sensitivity at the bite locations
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Trigger of severe vasospasm or new chilblain lesions
- Risk of tissue compromise in patients with peripheral arterial disease
- Delay of underlying connective tissue disease workup
- Permanent small scars at bite sites on cold-sensitive areas
- Who should not consider this
- Patients with active chilblain ulceration or open lesions
- Patients with suspected underlying lupus, antiphospholipid syndrome, or cryoglobulinemia (workup first)
- Patients with peripheral arterial disease (ABI <0.6) of the affected limb
- Patients with Raynaud's phenomenon with digital ulceration
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not tried strict cold avoidance and topical nifedipine
- What to ask your clinician
- Have I been worked up for connective tissue disease, antiphospholipid syndrome, or cryoglobulinemia?
- Have I tried strict cold avoidance and warm gloves/footwear?
- Am I a candidate for topical or oral nifedipine?
- Do I smoke, and have I been offered cessation support?
- Is my circulation normal (peripheral pulses, ABI)?
- What evidence specifically supports leech therapy for chilblains?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Sudden white, cold, or numb finger or toe that does not rewarm (possible critical limb ischemia)
- New ulceration or open sore at chilblain sites
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for chilblains or perniosis.
- Anecdotal reports do NOT establish efficacy versus cold avoidance, nifedipine, or smoking cessation.
- It does NOT replace connective tissue disease workup in atypical chilblains.
- It does NOT substitute for strict prevention measures, which are the foundation of management.
- It does NOT mean leech application is safe on cold-sensitive extremities with marginal circulation.
Safety cross-references
Clinical Profile
- Category
- dermatological
- ICD-10
- T69.1XXA, T69.1XXD
- Safety tier
- medium
Evidence Summary
Chilblains (pernio) are inflammatory acral lesions triggered by exposure to cold, damp, non-freezing temperatures, producing erythematous-violaceous papules or nodules on fingers, toes, ears, or nose, with itching, burning, or pain. Most cases are idiopathic; secondary forms occur with connective tissue disease (lupus pernio, chilblain lupus), cryoglobulinemia, or hematologic disease, and were noted with COVID-19. Evidence-based management is cold avoidance, smoking cessation, vasodilator therapy (nifedipine 20-60 mg/day), and topical mid-potency corticosteroids for acute flares. No published controlled trials of hirudotherapy exist for chilblains. Mechanistic rationale of local microcirculatory effect is intuitive but unsupported by clinical evidence; cold-related vasospasm is the underlying problem.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- Placement on chilblain lesion or any ischemic acral tissue (absolute)
- Untreated secondary cause (lupus, cryoglobulinemia, hematologic) — workup first
- Active digital ulceration or gangrene
- Severe Raynaud phenomenon with ulceration
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.